It has also been studied in atherosclerosis<ref name="pmid8188119">{{cite journal |vauthors=Toyoda K, Kitahara M, Yamashita T |title=[Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits] |language=Japanese |journal=Nippon Yakurigaku Zasshi |volume=103 |issue=5 |pages=231–9 |date=May 1994 |pmid=8188119 |doi= |url=|display-authors=etal}}</ref> and acute renal failure.<ref name="pmid7896060">{{cite journal |vauthors=Shudo C, Masuda Y, Sugita H, Tanaka S, Tomita K |title=Effects of efonidipine hydrochloride (NZ-105), a new calcium antagonist, against acute renal failure in rats |journal=Gen. Pharmacol. |volume=25 |issue=7 |pages=1451–8 |date=November 1994 |pmid=7896060 |doi= |url=}}</ref>
